The psychedelic medicine sector has entered its most important phase yet. The hype cycle is over. The speculative frenzy that pushed dozens of psychedelic companies into public markets between 2020 and 2022 has largely disappeared, taking with it weaker operators, undercapitalised hopefuls, and story-driven businesses that were never realistically positioned to commercialise regulated medicines. That […]
Already subscribed? Log in
US-listed BioAdaptives, Inc. (OTCID: BDPT) has signed a definitive agreement to acquire Xycota Biosciences LLC, a privately held biotechnology company developing experimental psychedelic medicines for psychiatric and neurological...
Canadian biotechnology company PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) has signed an agreement with Corealis Pharma Inc., a contract development and manufacturing organisation based in Laval,...
Definium Therapeutics (NASDAQ: DFTX) is set to present findings from three positive Phase 3 clinical trials of its LSD-based drug candidate, DT120 ODT, at the 2026 Neuroscience Education...
New preclinical findings suggest EB-003 can alter brain activity without producing some of the adverse neurological effects observed with DMT in mice. Enveric Biosciences (NASDAQ: ENVB) has reported...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
